What is Thymox?
Thymox, operating under Laboratoire M2, is a leader in developing and marketing biodegradable disinfectants. Their product line, featuring the active ingredient thymol derived from thyme oil, offers effective solutions against a spectrum of pathogens including bacteria, fungi, molds, and viruses like COVID-19. The company serves diverse markets such as animal health, agricultural crop protection, and hard surface disinfection, providing eco-friendly alternatives for critical hygiene needs. Their commitment to innovation extends to biopesticides and a range of specialized disinfectants, including all-purpose and farm-specific formulations.
How much funding has Thymox raised?
Thymox has raised a total of $4.6M across 1 funding round:
Series B
$4.6M
Series B (2017): $4.6M with participation from Cycle Capital Management and Desjardinsu2013Innovatech
Key Investors in Thymox
Cycle Capital Management
Cycle Capital Management is a venture capital firm specializing in building innovative clean technology companies globally, with a focus on DeepTech and circular innovation across North America and Europe.
Desjardins–Innovatech
Desjardins–Innovatech, part of the Desjardins Group, is a significant financial cooperative in North America, known for its strong presence and investment in innovative ventures.
What's next for Thymox?
The substantial enterprise-level capital infusion positions Thymox for accelerated growth and expanded market penetration. This strategic backing is expected to fuel further research and development, enhance production capabilities, and broaden the distribution of their innovative antimicrobial solutions. The company's focus on biodegradable and thymol-based products aligns with increasing global demand for sustainable and effective biosecurity measures, suggesting a strong trajectory for future expansion and potential new product introductions.
See full Thymox company page
